BIOMAT Database Logo BIOMAT Database Logo

Decreased protein C inhibitor after percutaneous transluminal coronary angioplasty in patients with acute myocardial infarction. 1995

M Tanigawa, and H Wada, and K Minamikawa, and Y Wakita, and S Nagaya, and T Mori, and S Tamaki, and H Nishikawa, and Y Kakuta, and T Nakano
Second Department of Internal Medicine, Mie University School of Medicine, Japan.

Plasma thrombin-antithrombin III complex (TAT), FDP-D-dimer, activated protein C (APC)-protein C inhibitor (PCI) complex, and tissue type plasminogen activator (t-PA), PA inhibitor-1 (PAI-I) were significantly increased in patients with acute myocardial infarction (AMI) at onset. These patients exhibited a hypercoagulable state and protein C activation at onset. The plasma PCI level at onset of AMI was within the normal range, but was significantly decreased after percutaneous transluminal coronary angioplasty (PTCA). After PTCA, plasma t-PA, FDP-D-dimer, and plasmin-alpha 2-plasmin inhibitor were increased but APC-PCI complex and TAT were not. The decrease in PCI after PTCA may have been caused by the activation of fibrinolysis. PCI may play an important role in the inhibition of fibrinolysis in stimulated or damaged endothelial cells. These findings suggest that the protein C pathway plays an important role in the onset of AMI and after PTCA.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009203 Myocardial Infarction NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION). Cardiovascular Stroke,Heart Attack,Myocardial Infarct,Cardiovascular Strokes,Heart Attacks,Infarct, Myocardial,Infarction, Myocardial,Infarctions, Myocardial,Infarcts, Myocardial,Myocardial Infarctions,Myocardial Infarcts,Stroke, Cardiovascular,Strokes, Cardiovascular
D010447 Peptide Hydrolases Hydrolases that specifically cleave the peptide bonds found in PROTEINS and PEPTIDES. Examples of sub-subclasses for this group include EXOPEPTIDASES and ENDOPEPTIDASES. Peptidase,Peptidases,Peptide Hydrolase,Protease,Proteases,Proteinase,Proteinases,Proteolytic Enzyme,Proteolytic Enzymes,Esteroproteases,Enzyme, Proteolytic,Hydrolase, Peptide
D010959 Tissue Plasminogen Activator A proteolytic enzyme in the serine protease family found in many tissues which converts PLASMINOGEN to FIBRINOLYSIN. It has fibrin-binding activity and is immunologically different from UROKINASE-TYPE PLASMINOGEN ACTIVATOR. The primary sequence, composed of 527 amino acids, is identical in both the naturally occurring and synthetic proteases. Alteplase,Plasminogen Activator, Tissue-Type,T-Plasminogen Activator,Tissue-Type Plasminogen Activator,Actilyse,Activase,Lysatec rt-PA,TTPA,Tisokinase,Tissue Activator D-44,Lysatec rt PA,Lysatec rtPA,Plasminogen Activator, Tissue,Plasminogen Activator, Tissue Type,T Plasminogen Activator,Tissue Activator D 44,Tissue Type Plasminogen Activator
D011486 Protein C A vitamin-K dependent zymogen present in the blood, which, upon activation by thrombin and thrombomodulin exerts anticoagulant properties by inactivating factors Va and VIIIa at the rate-limiting steps of thrombin formation.
D012016 Reference Values The range or frequency distribution of a measurement in a population (of organisms, organs or things) that has not been selected for the presence of disease or abnormality. Normal Range,Normal Values,Reference Ranges,Normal Ranges,Normal Value,Range, Normal,Range, Reference,Ranges, Normal,Ranges, Reference,Reference Range,Reference Value,Value, Normal,Value, Reference,Values, Normal,Values, Reference
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000990 Antithrombin III A plasma alpha 2 glycoprotein that accounts for the major antithrombin activity of normal plasma and also inhibits several other enzymes. It is a member of the serpin superfamily. Heparin Cofactor I,Antithrombin III-Alpha,Atenativ,Heparin Co-Factor I,Kybernin,Serpin C1,Thrombate III,Antithrombin III Alpha,Antithrombin IIIAlpha,Cofactor I, Heparin,Heparin Co Factor I

Related Publications

M Tanigawa, and H Wada, and K Minamikawa, and Y Wakita, and S Nagaya, and T Mori, and S Tamaki, and H Nishikawa, and Y Kakuta, and T Nakano
Delayed percutaneous transluminal coronary angioplasty after acute myocardial infarction.
February 1998, International journal of cardiology,
M Tanigawa, and H Wada, and K Minamikawa, and Y Wakita, and S Nagaya, and T Mori, and S Tamaki, and H Nishikawa, and Y Kakuta, and T Nakano
[Percutaneous transluminal coronary angioplasty in acute myocardial infarction].
September 1997, Zhonghua nei ke za zhi,
M Tanigawa, and H Wada, and K Minamikawa, and Y Wakita, and S Nagaya, and T Mori, and S Tamaki, and H Nishikawa, and Y Kakuta, and T Nakano
[Percutaneous transluminal coronary angioplasty in acute myocardial infarction].
March 1990, Ugeskrift for laeger,
M Tanigawa, and H Wada, and K Minamikawa, and Y Wakita, and S Nagaya, and T Mori, and S Tamaki, and H Nishikawa, and Y Kakuta, and T Nakano
Percutaneous transluminal coronary angioplasty in acute myocardial infarction.
April 1984, American heart journal,
M Tanigawa, and H Wada, and K Minamikawa, and Y Wakita, and S Nagaya, and T Mori, and S Tamaki, and H Nishikawa, and Y Kakuta, and T Nakano
Percutaneous transluminal coronary angioplasty for acute myocardial infarction.
April 1993, Internal medicine (Tokyo, Japan),
M Tanigawa, and H Wada, and K Minamikawa, and Y Wakita, and S Nagaya, and T Mori, and S Tamaki, and H Nishikawa, and Y Kakuta, and T Nakano
Percutaneous transluminal coronary angioplasty for acute myocardial infarction.
November 1989, Cardiology clinics,
M Tanigawa, and H Wada, and K Minamikawa, and Y Wakita, and S Nagaya, and T Mori, and S Tamaki, and H Nishikawa, and Y Kakuta, and T Nakano
[Percutaneous transluminal coronary angioplasty for acute myocardial infarction].
April 2003, Hunan yi ke da xue xue bao = Hunan yike daxue xuebao = Bulletin of Hunan Medical University,
M Tanigawa, and H Wada, and K Minamikawa, and Y Wakita, and S Nagaya, and T Mori, and S Tamaki, and H Nishikawa, and Y Kakuta, and T Nakano
[Percutaneous transluminal coronary angioplasty for acute myocardial infarction].
August 1994, Nihon rinsho. Japanese journal of clinical medicine,
M Tanigawa, and H Wada, and K Minamikawa, and Y Wakita, and S Nagaya, and T Mori, and S Tamaki, and H Nishikawa, and Y Kakuta, and T Nakano
Percutaneous transluminal coronary angioplasty and acute myocardial infarction.
January 1994, British journal of hospital medicine,
M Tanigawa, and H Wada, and K Minamikawa, and Y Wakita, and S Nagaya, and T Mori, and S Tamaki, and H Nishikawa, and Y Kakuta, and T Nakano
Percutaneous transluminal coronary angioplasty during acute myocardial infarction.
February 1988, Cardiology clinics,
Copied contents to your clipboard!